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Abstract
Purpose: To measure and compare the surface dose outside the treatment area at six different points of interest (POIs) for five
different breast cancer radiation treatment modalities by using thermo-luminescent dosimeters (TLDs). This experiment will
evaluate the magnitude of the dose due to scatter and leakage radiation at different areas outside the target on a patient that
could potentially lead, in the long term, to radiation induced secondary malignancies. Methods: TLD-100 were calibrated ac-
cording to the University of Wisconsin Radiation Calibration Laboratory protocol and then used for dose measurements at se-
lected POIs namely sternum, lower abdomen, contralateral breast, thyroid, shoulder, and eye. Twenty five breast cancer pa-
tients and the following modalities were included in this study: Strut-adjusted volume implant (SAVI), mammosite multi-lumen
(ML), Accuboost, electron boost and photon boost. The surface doses in all patients were measured in a single fraction. The
delivered target doses were normalized to 200 cGy. Finally, breast quadrant analysis was performed. Results: The maximum
average dose for each POI was as follows: Sternum 6.51 cGy (SD 2.93), lower abdomen 4.50 cGy (SD 2.63), contralateral breast
8.52 cGy (SD 3.86), thyroid 5.50 cGy (SD 2.75), shoulder 5.58 cGy (SD 2.77), and eye 2.65 cGy (SD 0.68). The highest POI dose
of 15.84 cGy was found in contralateral breast. Conclusion: The measured surface dose at each POI varies with the modality of
treatment. The surface doses show a strong correlation to the tumor bed location in the breast quadrant. The SAVI, electron
boost, and photon boost modalities had delivered smaller surface dose at POIs than the Accuboost and Mammosite ML modali-
ties. While the measured doses fall within the low range, its significance in producing second malignancies would require a
large cohort of patients and a longer follow up.
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Introduction
Breast conservation surgery combined with radiation has
become an accepted alternative to total mastectomy for se-
lected patients with early-stage breast cancer because of its
comparable overall survival rate and positive impact on
quality of life.1 About 30% of U.S. women with breast cancer
undergo breast conservation surgery with radiation therapy.2
It is reported that, irradiation of surrounding tissues during
breast radiotherapy can cause development of secondary
cancers within these tissues.3 Consequently, there is increas-
ing concern regarding radiation-related secondary cancer
risks in long term radiotherapy survivors and a need to eval-
uate cancer risks at high radiation doses.4
The doses at the points outside the treatment area are small
compared to the target dose. Nonetheless, these doses are of
clinical interest because they are given to large parts of the
body and there is a potential for long term adverse effects.5 In
addition, low doses of radiation also have potential to induce
secondary cancers.6, 7 Concern for risk of radiation-induced
malignancy is growing with the increasing number of cancer
patients and several publications have widely discussed the
probability of secondary malignancies after primary radiation
treatment.8, 9-19 Out-of-field doses due to radiation are re-
sponsible for affecting cataract formation, fetus, cardiac tox-
icity, infertility and hypothyroidism.5, 20-25
The estimated threshold doses for the most radiosensitive
tissues in humans are: 15 cGy for temporary sterility of testes,
50-200 cGy for detectable opacity of lens and 50 cGy for
depression of hematopoiesis.26 It is reported that about 22% of
[A part of this research was presented at American Brachytherapy Society (ABS) Annual Meeting, which was held on April 3rd, 2014 in San Diego, CA. It 
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secondary cancers are induced in regions more than 5 cm
away from the irradiated volume.27 The latency period for
secondary cancer development varies with tissue type. Over-
all, the median secondary tumor latency period is reported as
7.4 years.28
The surrounding normal tissues outside the treated area in-
evitably receive some radiation dose, regardless of the treat-
ment modality. Contributing factors include leakage from
housing source, scatter from beam modifiers, and internal
scatter from the patient.29 Accurate measurement of surface
dose allows for estimation of the damage risk especially to
those organs that are sensitive to relatively low doses of ra-
diation. Several papers are published on the evaluation of
peripheral and organ doses due to breast cancer radiothera-
py; among those the in vivo and phantom measurements
using thermo-luminescent dosimeters (TLDs), a computer-
ized Monte Carlo (MC) technique using a mathematical
phantom, and several commercial treatment planning soft-
ware (TPS).30-33 Their results vary from method to method,
i.e., the peripheral dose difference between TPS and MC was
reported up to 70%,34 while the mean difference between
MC out-of-field doses and TLD measurements was found
11.4% ± 5.9%.30The percent difference between the TPS and
TLD measurement skin doses was found in the range from
-15% to 44%.35
The peripheral doses at 20cm away from the target area was
found 2.52 cGy and 2.07 cGy using TLDs in LINAC and
tomotherapy delivery correspondingly, for a planning target
volume (PTV) dose of 200 cGy.36 However, the surface dose
measurement outside the treatment area at several points of
interest in a real patient using TLDs is limited.
There are several treatment modalities for breast cancer.
This study includes SAVI, Mammosite ML, Accuboost, Elec-
tron boost, Photon boost. SAVI uses 6, 8 or 10 peripheral
source channels with one center channel and inserted in
collapse form into the tumor cavity through a small incision
in the breast.37, 38 The catheters are then expanded to con-
form to the shape of the cavity and allow for precise delivery
of radiation. MammoSite ML consists of a balloon catheter
that is inserted into the lumpectomy then expanded, and
radiation is delivered through a tiny seed attached to the
catheter, irradiating the area surrounding the cavity.39, 40
Accuboost applies breast brachytherapy without invasive
catheters.
Two parallel-opposed beams are directed into the breast
maximizing the target dose uniformity and minimizing the
dose to the skin and other healthy breast tissues.41 The Boost
dose is radiation targeted at the tissue near the lumpectomy
site; this tissue needs the extra dose, because it is thought to
contain “pre-cancerous” cells, therefore it is most likely to
develop reoccurrences.42, 43 The modalities for supplementary
doses after lumpectomy are electrons and photon boosts.
Electron boost is the favored method of boost delivery, be-
cause electrons permit penetration of superficial tissues with
limited radiation deeper into the lung, heart and other in-
ternal organs. Photon boost is encouraged only for deep
seated tumors for better coverage with sparing of organ at
risk.44
The aim of this study is to measure and compare the surface
dose outside the irradiated volume in breast cancer patients at
six different POIs in the proximity of critical structures for
five different radiation treatment modalities: SAVI, Mam-
mosite ML, Accuboost, Electron boost and Photon boost.
Such study could be of interest to clinical investigation for the
risk of late radiation effects in a breast cancer patient as a
result of primary radiotherapy. The delivered doses for all
modalities were normalized to 200 cGy in order to compare
the doses in the POIs. The effective dose equivalent is esti-
mated for all modalities.
Methods and Materials
Calibration of TLDs and Sorting
The TLD-100 (92.5% 7LiF + 7.5% 6LiF) of size 3 × 3 × 0.89 mm3
detector was chosen because it is sensitive to electrons, pho-
tons and neutrons. The TLDs were calibrated according to the
protocol of the University of Wisconsin. First, 500 TLD-100
chips were annealed at a 400°C oven for one hour in an alu-
minum tray in order to de-excite all the traps in the crystal
and erase all residual doses. Then the TLDs were transferred
in an acrylic holder with numbered positions and placed in an
annealing oven at 80°C for 24 hours in order to redistribute
traps to the desired single peak glow curve. Then they were
cooled down to room temperature overnight. All the TLDs
were irradiated by a Hopewell G10 137Cs irradiator in the
UWRCL. The exposure of the 137Cs was 500 mR. The TLDs
were read by using a Harshaw-5500 automatic reader after 24
hours. The whole process was repeated three times, except for
the 400°C annealing process to determine the individual sen-
sitivities of the TLDs.
During the final sorting process, TLDs with a reading devia-
tion greater than 3% were ignored. Average readings more
than 51 nC and less than 36 nC were also ignored in order to
control the large variation of readings among the TLDs. The
average deviation (stand/mean) was 1.41%.
Energy and dose dependence of TLDs
The dose response of the TLD-100 material depends on the
energy that it has been exposed to.45 In the dose measure-
ments, the relative dose response depends on the energy that
has been used in calibrating the dosimeters. TLD-100 chips
were calibrated with a relatively high energy source (137Cs,
average energy 662 keV) so that the response of a megavolt-
age photon beam will be very close to the calibrated energy.
The used TLD intrinsic energy conversion factor for 192Ir to
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137Cs was 1.041 ± 0.018.35 For the electron beam of 6 MeV to
60Co the conversion factor was 0.965 ± 0.013 46 and for 60Co to
137Cs was 0.960.47
The response of the TLDs is also dose dependent. For low
doses, the response is linear for photons and electrons, but for
higher doses (>10 Gy) the response is non-linear.48 In this
study, the maximum dose delivered at the central axis of
target volume during treatment was 340 cGy. Therefore, a
linear model has been applied to normalize the doses.
Patient selection
Twenty five cases of breast cancer patients had been selected
to evaluate the skin surface dose outside the treatment area at
six different points for five different treatment modalities.
The number of patients in each modality, planning target
volume (PTV), patient’s body mass index (BMI), prescribed
dose and pertinent treatment planning software are given in
the Table 1. The patients were selected according to the pol-
icies and guidelines of the institutional review board (IRB) of
the Boca Raton Regional Hospital, Boca Raton, FL. Patients’
consent had been taken to participate in the study.
Points of interest (POIs)
The skin surface of sternum, lower abdomen, contralateral
breast (CLB), thyroid, shoulder, and eye (superficial surface of
eyelid) were chosen as POIs as shown in Figure 2. These POIs
are considered clinically important because of their high
radiation sensitivity.
FIG. 1: The absorbed doses outside the treatment area at six POIs
versus the treatment modalities. The delivered doses for all cases
were normalized to 200 cGy.
FIG. 2: A schematic diagram to show the points of interest (POIs). Six
points were selected for TLDs placement. (1) Sternum; (2) Lower
abdomen; (3) Contralateral breast (CLB); (4) Thyroid; (5) Shoulder;
(6) Eye. Abbreviations: TS = Treatment site; A = Left breast treatment
B = Right breast treatment.
Method of study
The calibrated TLDs were placed on the skin surface at six
different POIs of the patients by the same person to minimize
the placement errors of the chips. These points were selected
such that the region of interest was most proximal to the
tumor location. The TLDs were then exposed during patient
treatment and read for evaluation. In each set of TLDs, two
were held as control to account for shipping and transit dose.
The absorbed dose was calculated by taking into account the
background dose, an energy response factor, and a Cs-137





The patient’s data were grouped under each modality and on
tumor location in breast quadrant for comparison.
Quadrant analysis
Quadrant analysis was performed to investigate the rela-
tionship between the absorbed dose at the different POIs and
the area of breast where the tumor is located. For this pur-
pose, the breasts are divided into quadrants and named: Right
upper outer quadrant (RUOQ), Right lower outer quadrant
(RLOQ), Right upper inner quadrant (RUIQ), Right lower
inner quadrant (RLIQ), Left upper outer quadrant (LUOQ),
Left lower outer quadrant (LLOQ), Left upper inner quadrant
(LUIQ) and Left lower inner quadrant (LLIQ). From the
patients’ records, it was found that the numbers of tumor
location were: RUOQ (2), RLOQ (5), RUIQ (2), RLIQ (2),
LUOQ (4), LLOQ (3), LUIQ (2) and LLIQ (1). The records of 4
out of 25 patients did not include the quadrant information.
B BA
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Mammosite ML 4 26-60 8-12 21-29 340 Oncentra
Accuboost 7 29-80 9-15 20-25 180-200 Nucletron-ART
SAVI 6 20-66 6-10 24-50 340 Oncentra
Electron Boost 4 54-150 9-14 20-32 200 Eclipse
Photon Boost 4 55-174 6-14 22-32 200 Eclipse
Abbreviations: PTV = Planning target volume; BMI = Body mass index; TPS = Treatment planning software
TABLE 2: The averaged absorbed dose in centigray (cGy) outside the treatment area at six different POIs for the five studied modalities. The
standard deviations are given in parenthesis.
POI
Absorbed dose in cGy for the studied modalities
Accuboost SAVI ML ElectronBoost
Photon
Boost
Sternum 6.51 (2.93) 3.06 (1.28) 5.27 (2.12) 0.52 (0.20) 2.62 (1.82)
Abdomen 4.50 (2.64) 1.67 (1.22) 2.81 (2.26) 0.32 (0.18) 0.76 (0.11)
CLB 8.52 (3.87) 2.74 (1.49) 2.80 (1.22) 0.41 (0.24) 1.84 (0.69)
Thyroid 5.50 (2.75) 2.00 ( 0.73) 3.38 (1.03) 0.52 (0.13) 0.96 (0.55)
Shoulder 5.18 (2.21) 2.26 (1.11) 5.58 (2.77) 0.66 (0.16) 1.02 (0.42)
Eye 1.74 (0.84) 1.51 (0.52) 2.64 (0.69) 0.52 (0.29) 0.64 (0.20)
Results
The results of the out-of-field surface dose measurements on
these 25 breast cancer patients for five different treatment
modalities are listed in Table 2 and plotted in Figure 1. The
absorbed doses in each POI were averaged for each modality
group. As Figure 1 shows, the highest average skin surface
dose was measured at contralateral breast treated with Ac-
cuboost modality. The high standard deviations in Table 2 are
related to the number and specifics of patients in each mo-
dality.
From the quadrant analysis of the data in Table 3, it was
found that 10 patients had cancer at the left breast and 11
patients had cancer at the right breast while about 67% of
patients had a tumor in the outer quadrant. As Table 3 shows,
four out of six patients having a tumor in the inner quadrant
were treated with Accuboost. The ones with tumor in the
inner upper quadrant had received higher doses to the thy-
roid, contralateral breast and the sternum. In patients with
tumor in the left outer upper quadrant, the shoulder had
received the highest dose. Relatively higher skin surface doses
have been measured at the lower abdomen, contralateral
breast and the sternum compared to the other POIs for pa-
tients treated with a tumor in the lower inner quadrants.
From all the modalities and patients studied, the maximum
surface doses vary at the POIs with values: 15.84 cGy (7.92%)
in contralateral breast, 12.66 cGy (6.33%) in sternum, 11.50
cGy (5.75%) in thyroid, 11.13 cGy (5.56%) in shoulder, 3.86
cGy (1.93%) in eye and 8.6 cGy (4.30%) in lower abdomen.
The numbers in parentheses are the corresponding percent-
ages of the normalized delivered dose.
TABLE 3: Quadrant analysis result from the twenty one patients tre-
ated with different modalities. Tumor bed locations in the breast and
corresponding maximum absorbed dose to the POIs are also given.




1 (RLIQ) CLB (6.41 cGy)
1 (RUIQ) Thyroid (11.50 cGy)
1 (LUOQ) Shoulder (8.25 cGy)
1 (LUIQ) CLB (15.84 cGy)
1 (LLIQ) Sternum (12.66 cGy)
ML
2 (RUOQ) Shoulder (11.13)
1 (LUIQ) Sternum (3.72 cGy)
1 (RLOQ) Sternum (5.64 cGy)
SV
3 (RLOQ) Sternum (3.10 cGy),Shoulder (4.19 cGy)
2 (LUOQ) Sternum (2.75 cGy)
1 (LLOQ) Sternum (5.26 cGy)
PB
1 (RUIQ) Sternum (5.23 cGy)
1 (RLOQ) Sternum (1.12 cGy)
1 (RLIQ) Sternum (2.46 cGy)
1 (LLOQ) CLB (2.37 cGy)
EB 1 (LLOQ) Shoulder (0.78 cGy)1 (LUOQ) Eye (0.98 cGy)
Abbreviations: AB = Accuboost; ML = Mammosite multi lumen;
SV = SAVI; PB = Photon boost; EB = Electron boost
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PB EB vs PB
p-value 0.008 0.16 0.003 0.003 0.02 9E-04 4E-04 0.001 0.004 0.049
The two way analysis of variance (ANOVA) test was per-
formed to compare the average doses at POIs for the five
different treatment modalities. Results of the test are given in
Table 4. It can be seen that Accuboost and Mammosite mul-
ti-lumen are not significantly different (p = 0.16, at 5% sig-
nificant level). SAVI values are significantly different from
these two modalities (AB and ML) with p < 0.05. The
out-of-field skin surface doses measured with APBI (AB, SV
and ML) modalities are significantly different compared to
electron boosts or photon boosts (p < 0.05). In addition the
p-value for EB and PB are close to the significant level of 5%.
The effective dose (HE = ΣWTHT) provides a number that is
proportional to the radiobiological adverse effect from an
inhomogeneous type of radiation exposure. It has been de-
fined and introduced by ICRP for risk management purposes.
According to the ICRP (2007), the tissue specific weighting
factors (WT) for thyroid, breast, stomach, lungs, gonads and
remainder tissues are 0.04, 0.12, 0.12, 0.08 and 0.12 respec-
tively. Considering the closest tissues/organs from the skin
surface, the calculated effective doses for the studied modali-
ties are: Accuboost 3.45 rem, SAVI 1.45 rem, ML 2.46 rem,
electron boost 0.32 rem and photon boost 0.87 rem. The beam
quality factor for the photon and electrons are taken unity.
The neutron generation term is ignored because of the low
photon energy (less than 6 MV).
Discussion
This study shows that the measured absorbed doses at POIs
treated with the same modality display large variations. The
highest variation was found for the contralateral breast site
treated with the Accuboost modality with a range from 2.67
cGy to 15.84 cGy. The tumors were located in the left upper
outer quadrant (LUOQ) and the left upper inner quadrant
(LUIQ) correspondingly. The second major variation was
found in the shoulder treated with Mammosite ML with the
dose range between 2.52 cGy and 11.13 cGy. The tumors
were located in the left upper inner quadrant (LUIQ) and the
right upper outer quadrant (RUOQ) respectively.
The location of the tumor in the breast quadrant and dis-
tance of POIs from the treatment site are the two major fac-
tors influencing the dose to the POI, as expected from the
inverse square law. Patient’s BMI, size of tumor, size of
breast, duration of treatment, orientation of field, patients’
set up, applicators and catheters used during treatment could
be additional affecting factors in receiving different skin
surface doses at different POIs.
In the case of electron boosts, the measured out-of-field sur-
face doses were small in all POIs due to predominantly ion-
izing events with atomic electrons of the tissue, resulting to
absorbance of the incident electrons’ energy within a few
millimeters. However, in order to accurately justify the ab-
sorbed dose results with electron boost, calibration of TLDs
has to be done with an electron beam, whereas the TLDs of
the present study were calibrated with a photon beam.
Conclusion
The measured surface dose at each POI varies with the mo-
dalities of treatment. The surface doses show a strong corre-
lation to the tumor bed location in the breast quadrant. The
SAVI, electron boost, and photon boost had delivered small-
er surface doses at POIs than the Accuboost and Mammosite
ML modalities. While these doses are found within the low
range, a longer follow up and a large cohort of patients could
provide valuable information regarding the radiation in-
duced secondary malignancies. It should be reminded that
special care should be given to delivery parameters such as
patient set up, transfer tube orientation, applicator orienta-
tion, and field set up in order to minimize the surface dose.
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